Across 95 European ophthalmology phase 2 & 3 trials, 60 trials used at least one Contract Research Organization (CRO) or CTIS-listed support provider, equal to 63.2%. Parexel / Perceptive Informatics led with 14 supported trials, followed by Syneos Health with 13, Merit CRO with 11, and PPD / Thermo Fisher with 10. CRO demand was most strongly linked to multi-country and high-site-count execution: 26 of 27 trials with 4–6 countries used CRO support, and 27 of 29 trials with 21+ sites used CRO support.
Parexel / Perceptive Informatics appeared in 14 of 95 trials (14.7%), Syneos Health in 13 of 95 (13.7%), Merit CRO in 11 of 95 (11.6%), and PPD / Thermo Fisher in 10 of 95 (10.5%). The ranking counts each provider once per trial, after grouping obvious affiliate names under the same parent where appropriate.
Ophthalmology outsourcing is not limited to full-service CROs. The active provider mix includes global CROs, imaging-specialist providers, eClinical vendors, central laboratories, RTSM providers, and supply-chain providers, reflecting the operational burden of vision testing, retinal imaging, biologic delivery, and multi-country CTIS submissions.
CRO use rose sharply with European operating complexity. CRO support appeared in 26 of 27 trials with 4–6 countries (96.3%) and 15 of 16 trials with 7+ countries (93.8%). Site count was an equally strong signal: 27 of 29 trials with 21+ sites (93.1%) used CRO support.
The clearest outsourcing threshold is not participant volume alone; it is EU operational complexity. Once ophthalmology trials move beyond three countries or above 20 sites, CRO support becomes almost standard, likely because CTIS coordination, country-level Part II submissions, site start-up, imaging certification, and vendor oversight all scale together.
Participant volume showed a weaker but still visible outsourcing signal. The highest CRO-use band was 100–249 participants, with 17 of 22 trials using CRO support (77.3%). Trials with 50–99 participants had 17 of 25 CRO-supported trials (68.0%), while 250+ participant trials had 8 of 13 (61.5%).
Participant count alone does not explain CRO demand as strongly as country and site footprint. In ophthalmology, a smaller multi-country retinal imaging trial may require more external coordination than a larger but simpler single-country study. <